Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus – International Task Force
Date
2018Author
Kalra, Sanjay
Bahendeka, Silver
Sahay, Rakesh
Ghosh, Sujoy
Md, Fariduddin
Orab, Abbas
Ramaiya, Kaushik
Shammari, Sameer Al
Shrestha, Dina
Shaikh, Khalid
Abhayaratna, Sachitha
Shrestha K, Pradeep
Mahalingam, Aravinthan
Askheta, Mazen
Rahim, Aly Ahmed A
Eliana, Fatimah
Shrestha, Hari K.
Chaudhary, Sandeep
Ngugi, Nancy
Mbanya, Jean Claude
Aye, Than Than
Latt, Tint Swe
Akanov, Zhanay A.
Syed, Abbas Raza
Tandon, Nikhil
Unnikrishnan, A. G.
Madhu, S. V.
Jawa, Ali
Chowdhury, Subhankar
Bajaj, Sarita
Das, Ashok Kumar
Metadata
Show full item recordAbstract
For decades, sulfonylureas(SUs) have been important drugs in the antidiabetic therapeutic armamentarium. They have been used as monotherapy as well as combination therapy. Focus on newer drugs and concerns about the risk of severe hypoglycemia and weight gain with some SUs have led to discussion on their safety and utility. It has to be borne in mind that the adverse events associated with SUs should not be ascribed to the whole class, as many modern SUs, such as glimepiride and gliclazide modified release, are associated with better safety profiles. Furthermore, individualization of treatment, using SUs in combination with other drugs, backed with careful monitoring and patient education, ensures maximum benefits with minimal side effects. The current guidelines, developed by experts from Africa, Asia, and the Middle East, promote the safe and smart use of SUs in combination with other glucose‑lowering drugs.